Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance

Abstract Background Approximately 10% of non‐small cell lung cancers (NSCLCs) that harbor epidermal growth factor receptor (EGFR) gene mutations have in‐frame insertions in exon 20 of the EGFR gene. These tumors do not usually respond to currently available EGFR‐tyrosine kinase inhibitors (TKIs). Ta...

Full description

Bibliographic Details
Main Authors: Masaya Nishino, Kenichi Suda, Takamasa Koga, Shuta Ohara, Toshio Fujino, Junichi Soh, Vijaya Tirunagaru, Avanish Vellanki, Robert C. Doebele, Tetsuya Mitsudomi
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Thoracic Cancer
Subjects:
EGFR mutation
lung cancer
molecular targeted therapy
acquired resistance
secondary mutations
Online Access:https://doi.org/10.1111/1759-7714.13931

Internet

https://doi.org/10.1111/1759-7714.13931

Similar Items